Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS)

BACKGROUND: In 2014, the American Academy of Pediatrics stopped recommending palivizumab to otherwise healthy 29–34 weeks’ gestational age (wGA) infants aged <12 months at respiratory syncytial virus (RSV) season start. Here, we compare the burden of RSV hospitalizations (RSVH) and all-cause bron...

Descripción completa

Detalles Bibliográficos
Autores principales: Fergie, Jaime, Suh, Mina, Jiang, Xiaohui, Fryzek, Jon P, Gonzales, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974836/
https://www.ncbi.nlm.nih.gov/pubmed/32691037
http://dx.doi.org/10.1093/infdis/jiaa435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974836/
https://www.ncbi.nlm.nih.gov/pubmed/32691037
http://dx.doi.org/10.1093/infdis/jiaa435

Ejemplares similares